Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples

• Published in: British journal of clinical pharmacology Vol. 70; no. 4; pp. 580 - 587
• Main Authors: Koechling, Wolfgang, Hjortkjaer, Rolf, Tankó, László B.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.10.2010; Blackwell; Blackwell Science Inc
• Subjects: abarelix; Biological and medical sciences; cetrorelix; degarelix; Drug Safety; ganirelix; Gonadotropin-Releasing Hormone - analogs & derivatives; Gonadotropin-Releasing Hormone - antagonists & inhibitors; Gonadotropin-Releasing Hormone - pharmacology; histamine; Histamine - analysis; Histamine Release - drug effects; human skin; Humans; Medical sciences; Oligopeptides - pharmacology; Pharmacology. Drug treatments; Skin - drug effects; Human; Abarelix; Decapeptide; Peptides; Gonadotropin RH; Assisted procreation; Antihormone; Ganirelix; Degarelix; Hypothalamic hormone; Histamine; In vivo; Ex vivo; human skin; Models; Skin; Antagonist; Hormone releasing factor; Cetrorelix; Comparative study; Release

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT? • Systemic anaphylactic reactions have been described as rare but serious adverse effects of GnRH antagonists. • The chemical development of degarelix has devoted much attention to the elimination of this risk. • Side‐by‐side comparison of the histamine rele...